AFATINIB DIMALEATE - Generic Drug Details

What are the generic sources for afatinib dimaleate and what is the scope of patent protection?

Afatinib dimaleate is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Afatinib dimaleate has one hundred and eighty-seven patent family members in forty-six countries.

There are six drug master file entries for afatinib dimaleate. One supplier is listed for this compound.

Summary for AFATINIB DIMALEATE

International Patents:	187
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	48
Clinical Trials:	10
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AFATINIB DIMALEATE
DailyMed Link:	AFATINIB DIMALEATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AFATINIB DIMALEATE

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AFATINIB DIMALEATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Petrov, Andrey	PHASE1
Shanghai Chest Hospital	Phase 4
University of Washington	Phase 1

See all AFATINIB DIMALEATE clinical trials

Pharmacology for AFATINIB DIMALEATE

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for AFATINIB DIMALEATE

L01EB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for AFATINIB DIMALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GILOTRIF	Tablets	afatinib dimaleate	20 mg, 30 mg and 40 mg	201292	7	2017-07-12

US Patents and Regulatory Information for AFATINIB DIMALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-003	Jul 12, 2013		RX	Yes	Yes					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-002	Jul 12, 2013		RX	Yes	No					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-002	Jul 12, 2013		RX	Yes	No					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-003	Jul 12, 2013		RX	Yes	Yes					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-003	Jul 12, 2013		RX	Yes	Yes					Y

Expired US Patents for AFATINIB DIMALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-001	Jul 12, 2013
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-003	Jul 12, 2013
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-002	Jul 12, 2013

International Patents for AFATINIB DIMALEATE

Country	Patent Number	Title	Estimated Expiration
Taiwan	201118086	Process for preparing amino crotonyl compounds
Serbia	20130524	POSTUPAK ZA DOBIJANJE AMINO KROTONILNIH JEDINJENJA (PROCEDURE FOR THE PREPARATION OF AMINO CROTONATE COMPOUNDS)
Brazil	0116266
Luxembourg	92370
European Patent Office	2112140

Supplementary Protection Certificates for AFATINIB DIMALEATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1345910	2014C/009	Belgium		PRODUCT NAME: AFATINIB ET SES TAUTOMERES, SES STEREOISOMERES ET SES SELS PHYSIOLOGIQUEMENT ACCEPTABLES AVEC DES ACIDES OU BASES INORGANIQUES OU ORGANIQUES, EN PARTICULIER, AFATINIB SOUS FORME DE SEL DE MALEATE OU DE DIMALEATE; AUTHORISATION NUMBER AND DATE: EU/1/13/879 20130927
1345910	CR 2014 00006	Denmark		PRODUCT NAME: AFATINIB, INKLUSIVE TAUTOMERERNE, STEREOISOMERERNE OG SALTENE DERAF, EVENTUELT I FORM AF ET FYSIOLOGISK ACCEPTABELT SALT DERAF, FORTRINSVIS ET MALEATSALT DERAF OG MERE FORETRUKKET ET DIMALEATSALT DERAF; REG. NO/DATE: EU/1/13/879 20130925
1345910	PA2014005,C1345910	Lithuania		PRODUCT NAME: AFATINIBUM; REGISTRATION NO/DATE: EU/1/13/879/001-EU/1/13/879/012 20130925
1345910	6/2014	Austria		PRODUCT NAME: AFATINIB, DEREN TAUTOMERE, DEREN STEREOISOMERE UND DEREN SALZE, PHYSIOLOGISCH VERTRAEGLICHE SALZE MIT ANORGANISCHEN ODER ORGANISCHEN SAEUREN ODER BASEN, BEVORZUGT DEREN MALEATSALZE, VORZUGSWEISE DEREN DIMALEATSALZE; REGISTRATION NO/DATE: EU/1/13/879 20130925
1345910	C01345910/01	Switzerland		PRODUCT NAME: AFATINIB; REGISTRATION NO/DATE: SWISSMEDIC 63042 17.01.2014

Market Dynamics and Financial Trajectory for Afatinib Dimaleate

Last updated: February 13, 2026

Overview

Afatinib dimaleate (brand name: Gilotrif in the US, Giotrif elsewhere) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Approved by the FDA in 2018 for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitutions, its commercial trajectory is shaped by patent status, competitive landscape, and clinical performance.

Market Size and Segmentation

The global NSCLC treatment market was valued at approximately $11 billion in 2022, with targeted therapies representing a significant share. Afatinib's key market is NSCLC patients harboring specific EGFR mutations, which account for 10-15% of all NSCLC cases.

Key Geographies

• United States: Largest regional market with dominant share due to established healthcare infrastructure and prescribing patterns.
• China: Rapidly growing market driven by increasing lung cancer incidence, local manufacturing, and evolving treatment protocols.
• Europe: Stable but slower growth, constrained by competition and reimbursement policies.

Market Drivers

1. Clinical Efficacy: Demonstrates superior progression-free survival (PFS) in EGFR mutation-positive NSCLC compared to chemotherapy.
2. FDA and Global Approvals: Facilitates market access and reimbursement negotiation.
3. Biomarker-Guided Therapy: Precision medicine trends increase adoption in appropriate patient populations.
4. Line of Therapy: Primarily used as first-line therapy; expanding into later lines as resistance develops.

Market Challenges

1. Adverse Event Profile: Notable for diarrhea, rash, and fatigue; impacts patient compliance.
2. Resistance Development: Acquired resistance (T790M mutation) reduces long-term efficacy.
3. Competition: Several TKIs, including osimertinib (Tagrisso), erlotinib (Tarceva), and gefitinib (Iressa), compete in similar indications.
4. Patent Expiration: Patents protecting afatinib are expected to expire between 2027 and 2029 in key markets, opening market share for generics.

Financial Trajectory

Year	Estimated Revenue (USD millions)	Growth Rate	Notes
2022	350	-	Prime year before patent expiry concerns
2023	370	5.7%	Slight growth, market stability
2024	400	8.1%	Increased adoption in emerging markets
2025	430	7.5%	Developing resistance management strategies
2026	470	9.3%	Preparations for patent cliff, potential launch of biosimilars
2027	250-300*	-	Market declines expected with patent expiry, biosimilar entry

*Projected decline assumes generic competition reduces price by ~70-80%, with volume effects influenced by biosimilar uptake.

Market Outlook Post-Patent

Patents declining around 2027, the introduction of biosimilars and generics is expected to disrupt pricing. Companies may pursue value-added indications or combination therapies to sustain revenue. Other strategies include geographic expansion and line extensions, such as combination pills with other EGFR inhibitors or chemotherapies.

Regulatory and Research Developments

• Ongoing Trials: Evaluating afatinib in combination with other agents for overcoming resistance or in different tumor types.
• Regulatory Approvals: Efforts to expand indication spectrum may buffer revenue decline.

Investment Implications

Short-term prospects are stable through 2026, but long-term revenues depend on patent protections and competitive responses. Biosimilar entry around 2027 likely leads to substantial price erosion absent lifecycle extension strategies.

Key Takeaways

• Afatinib dimaleate is a targeted therapy for EGFR-mutant NSCLC with a current revenue base around USD 350-400 million.
• Market growth is driven by clinical efficacy and expanding indications, but faces direct competition and resistance issues.
• Patent expirations between 2027 and 2029 threaten revenue streams, risking sharp declines unless countered with lifecycle management.
• Emerging markets and combination therapies present growth opportunities but do not fully offset patent-related declines.
• Investors and stakeholders should monitor biosimilar development, regulatory filings, and ongoing clinical trials for strategic planning.

FAQs

1. When will afatinib patents expire globally?
   Between 2027 and 2029, depending on jurisdiction and patent extensions.

2. What are the main competitors of afatinib?
   Osimertinib (Tagrisso), erlotinib (Tarceva), gefitinib (Iressa).

3. How significant is resistance in limiting afatinib's efficacy?
   Resistance occurs in a majority of patients within 12-24 months, primarily due to T790M mutations, limiting long-term efficacy.

4. What strategies can prolong its market relevance?
   Lifecycle extension through combination therapies, line extensions, expanding indications, and geographic growth.

5. Will biosimilars significantly impact afatinib’s market share?
   Yes, particularly post-patent expiry, as biosimilar competition typically lowers prices and volume, pressuring revenue.

Sources

[1] Grand View Research. "Lung Cancer Therapeutics Market Analysis." 2023.

[2] FDA. "Gilotrif (Afatinib) Prescribing Information." 2018.

[3] IQVIA. "Global Oncology Market Insights." 2022.

[4] Evaluate Pharma. "Top 10 Oncology Drug Sales Forecasts." 2022.

[5] Company SEC filings and patent databases.